JP2025503176A5 - - Google Patents
Info
- Publication number
- JP2025503176A5 JP2025503176A5 JP2024544412A JP2024544412A JP2025503176A5 JP 2025503176 A5 JP2025503176 A5 JP 2025503176A5 JP 2024544412 A JP2024544412 A JP 2024544412A JP 2024544412 A JP2024544412 A JP 2024544412A JP 2025503176 A5 JP2025503176 A5 JP 2025503176A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- day
- pharmaceutical composition
- composition according
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263304424P | 2022-01-28 | 2022-01-28 | |
| US63/304,424 | 2022-01-28 | ||
| PCT/EP2023/051979 WO2023144290A1 (en) | 2022-01-28 | 2023-01-27 | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503176A JP2025503176A (ja) | 2025-01-30 |
| JP2025503176A5 true JP2025503176A5 (enExample) | 2026-02-10 |
Family
ID=85158800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544412A Pending JP2025503176A (ja) | 2022-01-28 | 2023-01-27 | びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20250115665A1 (enExample) |
| EP (1) | EP4469082A1 (enExample) |
| JP (1) | JP2025503176A (enExample) |
| KR (1) | KR20240135663A (enExample) |
| CN (1) | CN118613281A (enExample) |
| AU (1) | AU2023214116A1 (enExample) |
| CA (1) | CA3243415A1 (enExample) |
| IL (1) | IL314344A (enExample) |
| MX (1) | MX2024008833A (enExample) |
| TW (1) | TW202345895A (enExample) |
| WO (1) | WO2023144290A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022013797A (es) | 2020-05-08 | 2022-11-30 | Genmab As | Anticuerpos biespecificos contra cd3 y cd20. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| SG11201401422VA (en) | 2011-10-27 | 2014-09-26 | Genmab As | Production of heterodimeric proteins |
| ME03675B (me) | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| KR20170029565A (ko) * | 2014-07-11 | 2017-03-15 | 셀진 코포레이션 | 암 치료를 위한 병용요법 |
| US10544220B2 (en) | 2015-01-08 | 2020-01-28 | Genmab A/S | Bispecific antibodies against CD3 and CD20 |
| CN111787948A (zh) | 2018-02-09 | 2020-10-16 | 健玛保 | 包含针对cd3和cd20的双特异性抗体的药物组合物及其用途 |
| IL283218B2 (en) * | 2018-11-16 | 2025-11-01 | Juno Therapeutics Inc | Dosing methods of engineered T cells for the treatment of malignant B cells |
| CA3190376A1 (en) * | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
-
2023
- 2023-01-27 MX MX2024008833A patent/MX2024008833A/es unknown
- 2023-01-27 CA CA3243415A patent/CA3243415A1/en active Pending
- 2023-01-27 EP EP23702966.5A patent/EP4469082A1/en active Pending
- 2023-01-27 KR KR1020247028130A patent/KR20240135663A/ko active Pending
- 2023-01-27 IL IL314344A patent/IL314344A/en unknown
- 2023-01-27 JP JP2024544412A patent/JP2025503176A/ja active Pending
- 2023-01-27 WO PCT/EP2023/051979 patent/WO2023144290A1/en not_active Ceased
- 2023-01-27 US US18/833,261 patent/US20250115665A1/en active Pending
- 2023-01-27 AU AU2023214116A patent/AU2023214116A1/en active Pending
- 2023-01-27 CN CN202380018858.8A patent/CN118613281A/zh active Pending
- 2023-01-27 US US18/160,386 patent/US20230241211A1/en active Pending
- 2023-01-30 TW TW112103163A patent/TW202345895A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023541860A5 (enExample) | ||
| JP2023542289A5 (enExample) | ||
| JP2023541858A5 (enExample) | ||
| JP2023542290A5 (enExample) | ||
| JP2023524149A5 (enExample) | ||
| JP2025138634A (ja) | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 | |
| JP2021501162A5 (enExample) | ||
| JP2023542092A5 (enExample) | ||
| JP2023542291A5 (enExample) | ||
| JP6278536B2 (ja) | 関節炎治療 | |
| JP2021514973A5 (enExample) | ||
| CA2648223A1 (en) | Use of il-i antibodies for treating ophthalmic disorders | |
| JP2009532336A5 (enExample) | ||
| CA2478049A1 (en) | Humanized antibodies that recognize beta amyloid peptide | |
| JP2025032102A5 (enExample) | ||
| JP2022512875A5 (enExample) | ||
| JP2024534602A5 (enExample) | ||
| WO2017059813A1 (zh) | 抗乙肝表面抗原的抗体及其用途 | |
| US20240368290A1 (en) | Tmem219 antibodies and therapeutic uses thereof | |
| CN112480259B (zh) | 抗tnfr2抗体及其用途 | |
| JP2025503176A5 (enExample) | ||
| JP2020505350A5 (enExample) | ||
| JP2025503177A5 (enExample) | ||
| JP2024540435A5 (enExample) | ||
| JP2023546504A5 (enExample) |